Donepezil Hydrochloride Tablet
Product Images NDC 68788-8711

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 68788-8711). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Donepezil HCl Tablets 5mg (5mg 30s)

This is a description of Donepezil HCI Tablets 5mg, which is a generic version of the medication Aricept. Each film-coated tablet contains 5mg of donepezil hydrochloride USP. The tablets are round, white, and imprinted with "ET 39". They are manufactured by ACI HealthCare Limited. The tablets should be stored at 20° - 25°C (68° - 77°F) with excursions permitted to 15° - 30°C (59° - 86°F). The medication should be kept out of the reach of children. The directions on how to take the tablets are available in English and Spanish. It is important to note that federal law prohibits the transfer of this drug to anyone other than the patient for whom it was prescribed.*

FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)

FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)

Cumulative Percentage of Patients for Donepezil Hydrochloride 10 mg/day and Placebo in relation to ADCS-ADL Change from Baseline.*

FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)

This text seems to describe a comparison of clinical improvement or decline in patients receiving different doses of Donepezil Hydrochloride over a specific period of time (12-18 weeks). The data may reflect the change from baseline in terms of least squares mean, categorized as clinical improvement or decline.*

FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)

FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)

This text seems to be labeling a rating scale for assessing improvement in patients taking different dosages of Donepezil Hydrochloride for treatment. The scale includes categories such as "Markedly improved," "Moderately improved," "Minimally improved," "No change," "Worse," and varying degrees of worse labeled as "Minimally worse," "Moderately worse," and "Markedly worse." Each category allows evaluation of the patient's condition based on the CIBIC-plus Rating scale.*

FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)

FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)

This text seems to describe a chart or table showing the percentage of patients that experienced varying levels of improvement in a medical condition. The categories include "Markedly improves," "Improved," "Changed," "Worse," and "No change." The table may be related to hydrochloride or placebo medication, with a reference to a CIBIC-plus rating.*

FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)

This text appears to provide information on the ADAS-cog Change from Baseline in a clinical trial comparing the effects of treatment with Donepezil Hydrochloride 10mg/day, Donepezil Hydrochloride 5mg/day, and Placebo. The data suggests the clinical outcomes in terms of improvement and decline, possibly related to drug efficacy.*

FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)

FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)

This data appears to be related to a study or evaluation involving patients and different treatments. It shows percentages of patients at different improvement levels in relation to treatments like Donepezil Hydrochloride and Placebo. The CIBIC-plus rating is also mentioned.*

FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)

This text provides information on the change from baseline in clinical improvement after 3 months of drug treatment with Donepezil Hydrochloride 10 mg/day compared to the placebo. The mean values with standard errors are likely depicted for each group.*

FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)

FDA Label Image

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)

This text provides information about the change from baseline in activities of daily living (ADL) for patients receiving Donepezil Hydrochloride 10 mg/day compared to those on placebo after 3 months of drug treatment. The data may indicate clinical improvement in ADL for the group receiving Donepezil Hydrochloride.*

FDA Label Image

Chemical Structure (Donepezil Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.